Juan‐Manuel Sancho

Author

Juan‐Manuel Sancho

Hospital Universitari Germans Trias i Pujol ORCID

Also Known As

Antonio Salar, Guillermo Rodríguez, J M Sancho, J M Santos Sancho, J M. Sancho, J Sancho, J. L. Bello-López, J. M. Sancho, J. M. Sancho Cia, J. Martínez Sancho

404

Publications

5.3K

Citations

H-Index

Concepts

All Affiliations

Hospital Universitari Germans Trias i Pujol Institut Català d'Oncologia Universitat Autònoma de Barcelona Duran i Reynals Hospital Hospital Del Mar

About

Juan‐Manuel Sancho is an author at Hospital Universitari Germans Trias i Pujol specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	32	1.7K
2	Health Sciences	7	7	281
3	Public Health	1	1	19
4	Biochemistry	1	1	13
5	Biomedical Engineering	1	1	13

Juan‐Manuel Sancho

Publications

4.5K

Citations

H-Index

Page 1

	Year	Citations
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo, The Lancet Haematology Hematological MalignancyLymphoid NeoplasiaMedicineHematologyPathology	2020	324
Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy Gonzalo Gutiérrez, Teresa M. Cardesa‐Salzmann, Fina Climent, Blood	2011	317
MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy Alexandra Valera, Armando López‐Guillermo, Teresa M. Cardesa‐Salzmann, Haematologica ImmunologyPathologyMyc AmplificationsImmunotherapyTumor Biology	2013	225
Identification of Leptomeningeal Disease in Aggressive B-Cell Non-Hodgkin's Lymphoma: Improved Sensitivity of Flow Cytometry Sandra Quijano, Antonio López, Juan‐Manuel Sancho, Journal of Clinical Oncology	2009	214
Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets Kennosuke Karube, Anna Enjuanes, Iván Dlouhy, Leukemia	2017	178
R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study E. Condé, Montserrat Arnán, Miguel Canales, Haematologica	2008	169
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial Judith Trotman, Sally F. Barrington, David Belada, The Lancet Oncology Lymphoid NeoplasiaEnd-of-induction Pet ResponseMedicinePrognostic ValueFollicular Lymphoma	2018	152
Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma Gloria Iacoboni, Guillermo Villacampa, Núria Martínez‐Cibrián, Cancer Medicine	2021	131
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma Mi Kwon, Gloria Iacoboni, Juan Luís Reguera, Haematologica	2022	122
Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia Cristina Prat, Juan‐Manuel Sancho, José Domínguez, Leukemia & lymphoma/Leukemia and lymphoma	2008	117

Page 1